Effect of Vojta or Reflex locomotion therapy on the gross motor function of children with cerebral palsy

Organizational Data

DRKS-ID:
DRKS00014775
Recruitment Status:
Recruiting stopped (after recruiting started)
Date of registration in DRKS:
2018-05-25
Last update in DRKS:
2020-05-08
Registration type:
Retrospective

Acronym/abbreviation of the study

VTCP

URL of the study

No Entry

Brief summary in lay language

The goal of this study is to quantify improvements on the speed of motor development in children with cerebral palsy, when a Vojta or Reflexlocomotion therapy program is implemented. Vojta Therapy is a physiotherapy technique widely used in the paediatric rehabilition. The hipothesis is that this therapy can increase the speed of gross motor function at early stages of this condition. Therefore, children at risk of neurological conditions under 18 month of age could participate in this study.

Brief summary in scientific language

Gross motor function and mobility have important roles for classification, assessment and research involving children with neuromotor disorders. Gross Motor Function Measure (GMFM) could be currently considered as gold standard for the quantification of gross motor function in the pediatric rehabilitation. These follow ups of thousands of children with cerebral palsy described the long term development of their gross motor function and defined five unalterable levels of severity. By the age of six, stability over time on the prognosticated level of mobility is expected. Even if GMFM was not designed to assess outcomes of therapeutic interventions, some author used its centiles to compare individual long term effects. On the other hand, uncompleted items of GMFM assessments are used as short term therapeutic goals and therefore, individually controlled comparison of the speed of acquisition of gross motor function seems to be possible within each range. Reflex Locomotion (RL) or Vojta Therapy has been reported clinically beneficial for strength, movement and motor activities in individual cases and is being considered within the second of three levels of evidence in interventions for cerebral palsy . Poor study design casted a shadow over the positive results in previous studies about Reflex Locomotion including lack of random sequence generation, concealed allocation, study blinding, incomplete outcome data collection and selective reporting. RL therapy was developed by Prof Vojta and uses locomotor patterns activated “reflexogenically”. Reflex Locomotion does not refer to the neuronal regulation, but is rather related to therapeutically applied external stimuli and their automatic movement responses. The afferent input of RL therapy generates important cortical and subcortical changes, especially in the ipsilateral putamen. The resulting outputs are differential responses that seem to be located in the brainstem and cerebellum, pontomedullary reticular formation and posterior cerebellar hemisphere and vermis. These automatic motor patterns aim to change task-related motor activation and its associated postural control , as well as to release and facilitate the development of the ontogenic postural function. RL Therapy has been reported clinically beneficial for strength, movement and motor activities in individual cases and is being considered within the second of three levels of evidence in interventions for cerebral palsy . Poor study design casted a shadow over the positive results in previous studies about RL including lack of random sequence generation, concealed allocation, study blinding, incomplete outcome data collection and selective reporting. The ethical limitations of randomized untreated control groups or placebo interventions limit the quality of the intervention in this field. Family participation in the decision making process is highly emphasized, and its integration on the therapeutic handling reduces economic cost and commuting times, and increases the dosing possibilities. The automatic motor patterns activated with Reflex Locomotion therapy aim to change task-related motor activation and its associated postural control , as well as to release and facilitate the development of the ontogenic postural function. Because functional training of compensatory strategies is not emphasized, gross motor improvements after Reflex Locomotion intervention seems to depend on the activation of the postural frame required for their acquisition, reducing compensatory strategies during the subsequent environment exposure. Our hypothesis is that there is an improvement on the postural function and therefore, on the speed of acquisition of gross motor function from the first weeks of application of Reflex Locomotion Therapy in children with neuromotor disorders. The purposes of this trial were to understand the effect of Reflex Locomotion therapy on the GMFM of children with cerebral palsy without specific training of its items, as well as to understand what role plays its dosage. METHODS Our clinical trial was designed to quantify changes in gross motor function after two months of Reflex Locomotion intervention. Children carried on clinically with the intervention but this short period would allow us to attribute changes to Reflex Locomotion, controlling better the influence of other factor (such as age maturation or other therapy inputs). This design will not allow us to understand long term effects, but the potentiality to facilitate motor and postural function development.

Health condition or problem studied

ICD10:
G80 - Cerebral palsy
Healthy volunteers:
No Entry

Interventions, Observational Groups

Arm 1:
RL therapy will be carried out once a week for 2 months, by a trained physiotherapist. This therapist will also train the parents in the exercises to establish a daily home program (between one and four times per day). Therapist administer pressure to defined zones on the body in a patient who is in a prone, supine or side lying position. Two movement complexes will be used: “reflex creeping” and “reflex rolling”.

Endpoints

Primary outcome:
Outcome Name: Gross motor function Method of measuremente: Gross Motor Funcion Measure (GMFM). Timepoint: after 2 months of treatment
Secondary outcome:
Outcome Name: Therapy Dossagement Method of measuremente: Times/day Timepoint: after 2 months of treatment

Study Design

Purpose:
Treatment
Allocation:
N/A (single arm study)
Control:
  • Uncontrolled/single arm
Phase:
N/A
Study type:
Interventional
Mechanism of allocation concealment:
No Entry
Blinding:
No
Assignment:
Single (group)
Sequence generation:
No Entry
Who is blinded:
No Entry

Recruitment

Recruitment Status:
Recruiting stopped (after recruiting started)
Reason if recruiting stopped or withdrawn:
Due to Covid19 crisis, the assessment and treatment of pacients cannot be currently carried out. Due to the uncertain situation, recruitment in Germany could not be started and therefore temporary closing of the trial has been agreed to. Calculations will be done with the current sample already recruited.

Recruitment Locations

Recruitment countries:
  • Germany
  • Spain
  • United Kingdom
Number of study centers:
Multicenter study
Recruitment location(s):
  • Doctor's practice Siegen
  • Other Balance physiotherapy performance LTD. London (United Kingdom)
  • University medical center Hospital Teresa Herrera. A Coruña University A Coruña (Spain)
  • Other Clinica de Rehabilitacion. Madrid (Spain)

Recruitment period and number of participants

Planned study start date:
2018-05-04
Actual study start date:
2018-05-04
Planned study completion date:
No Entry
Actual Study Completion Date:
No Entry
Target Sample Size:
30
Final Sample Size:
21

Inclusion Criteria

Sex:
All
Minimum Age:
1 Months
Maximum Age:
18 Months
Additional Inclusion Criteria:
Male and female between zero and 18 months of age with neurological findings consistent with neuromotor disorders were recruited when the family inquired Reflex Locomotion therapy in different physiotherapy clinics in Spain, Germany and London (United Kingdom). The diagnosis of cerebral palsy can not be always confirmed within such an early stage, and neuromuscular disorders or other conditions that could affect motor performance need to be ruled out; therefore, the data of the children were included retrospectively on a later stage when the diagnosis was confirmed. In addition, participants’ parents or guardians gave informed consent. The previous therapeutic trajectory was not considered within the exclusion criteria for two reasons: their effect would be already included within the speed of motor development before RL, and also because all the children were controlled with themselves.

Exclusion Criteria

Data of the children are excluded if they introduced another therapy input or they dropped any of the previous ones during the two months of RL intervention (pharmacological, surgical or rehabilitative). For ethical reasons, this was not specified to the families who agreed to join the trial, in order not to influence their future therapeutic decisions.

Addresses

Primary Sponsor

Address:
Faculty of Medicine, University of Murcia, Spain. V. de la Arrixaca University Hospital, Department of Traumatology, Murcia, Spain.
Dr. PhD in Medicine Fernando Santonja-Medina
Calle Francisco Jimenez Ruiz, 27
30110 Murcia
Spain
Telephone:
+34666594989
Fax:
+34666594989
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.santonjatrauma.es
Investigator Sponsored/Initiated Trial (IST/IIT):
Yes

Contact for Scientific Queries

Address:
University of Murcia
Dr. PhD in Physiotherapy Jose Manuel Sanz-Mengibar
7 Newberry Mews
SW4 7EL London
United Kingdom
Telephone:
+447726764081
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.vojta.co.uk

Contact for Public Queries

Address:
University of Murcia
PhD in Physiotherapy Jose Manuel Sanz-Mengibar
7 Newberry Mews
SW4 7EL London
United Kingdom
Telephone:
+447726764081
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.vojta.co.uk

Principal Investigator

Address:
University of Murcia
Dr. PhD in Physiotherapy Jose Manuel Sanz-Mengibar
7 Newberry Mews
SW4 7EL London
United Kingdom
Telephone:
+447726764081
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.vojta.co.uk

Sources of Monetary or Material Support

Institutional budget, no external funding (budget of sponsor/PI)

Address:
University of Murcia
7 Newberry Mews
SW4 7EL London
United Kingdom
Telephone:
+447726764081
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.vojta.co.uk

Ethics Committee

Address Ethics Committee

Address:
Comisión de Ética de Investigación de la Universidad de Murcia [Murcia University (Spain)]
Dr. Phd Antonio Juan García Fernández
Vicerrectorado de Investigación. UNIVERSIDAD DE MURCIA. Campus de Espinardo
30071 Murcia
Spain
Telephone:
0034868883614
Fax:
0034868883614
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.um.es/web/comision-etica-investigacion/

Vote of leading Ethics Committee

Vote of leading Ethics Committee
Date of ethics committee application:
2018-03-01
Ethics committee number:
ID: 1823/2018
Vote of the Ethics Committee:
Approved
Date of the vote:
2018-03-09

Further identification numbers

Other primary registry ID:
No Entry
EudraCT Number:
No Entry
UTN (Universal Trial Number):
No Entry
EUDAMED Number:
No Entry

IPD - Individual Participant Data

Do you plan to make participant-related data (IPD) available to other researchers in an anonymized form?:
No Entry
IPD Sharing Plan:
No Entry

Study protocol and other study documents

Study protocols:
No Entry
Study abstract:
No Entry
Other study documents:
No Entry
Background literature:
No Entry
Related DRKS studies:
No Entry

Publication of study results

Planned publication:
No Entry
Publikationen/Studienergebnisse:
No Entry
Date of first publication of study results:
No Entry
DRKS entry published for the first time with results:
No Entry

Basic reporting

Basic Reporting / Results tables:
No Entry
Brief summary of results:
No Entry